JP2015537028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015537028A5 JP2015537028A5 JP2015542751A JP2015542751A JP2015537028A5 JP 2015537028 A5 JP2015537028 A5 JP 2015537028A5 JP 2015542751 A JP2015542751 A JP 2015542751A JP 2015542751 A JP2015542751 A JP 2015542751A JP 2015537028 A5 JP2015537028 A5 JP 2015537028A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- scar
- independently
- skin wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 28
- 231100000241 scar Toxicity 0.000 claims description 26
- 206010072170 Skin wound Diseases 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 208000032544 Cicatrix Diseases 0.000 claims description 5
- 230000037387 scars Effects 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 230000036573 scar formation Effects 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 208000009043 Chemical Burns Diseases 0.000 claims description 2
- 208000034693 Laceration Diseases 0.000 claims description 2
- 208000002847 Surgical Wound Diseases 0.000 claims description 2
- 206010053615 Thermal burn Diseases 0.000 claims description 2
- 238000005299 abrasion Methods 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000001969 hypertrophic effect Effects 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 208000018380 Chemical injury Diseases 0.000 claims 1
- 206010041899 Stab wound Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- ZXRNXIUNEPOVTF-FXYIOBSRSA-N C[C@@H](CCc(nccc1)c1OCc1ccccc1)/C(/C)=C/C=C\C Chemical compound C[C@@H](CCc(nccc1)c1OCc1ccccc1)/C(/C)=C/C=C\C ZXRNXIUNEPOVTF-FXYIOBSRSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GOZYDZKZNKSXNG-UHFFFAOYSA-N CC(Cc(cc1)ccc1C(C)=O)C(N(Cc1ccccc1C(F)(F)F)c(cc1)c(C)cc1F)=O Chemical compound CC(Cc(cc1)ccc1C(C)=O)C(N(Cc1ccccc1C(F)(F)F)c(cc1)c(C)cc1F)=O GOZYDZKZNKSXNG-UHFFFAOYSA-N 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N Cc1nnn[nH]1 Chemical compound Cc1nnn[nH]1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- BXLOSDFUQRTRSZ-UHFFFAOYSA-N OC(c1ccc(CC2Sc(cccc3)c3N(Cc3cc(F)ccc3C(F)(F)F)C2=O)cc1)=O Chemical compound OC(c1ccc(CC2Sc(cccc3)c3N(Cc3cc(F)ccc3C(F)(F)F)C2=O)cc1)=O BXLOSDFUQRTRSZ-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000036575 thermal burns Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727574P | 2012-11-16 | 2012-11-16 | |
| US61/727,574 | 2012-11-16 | ||
| PCT/US2013/069919 WO2014078434A1 (en) | 2012-11-16 | 2013-11-13 | Compounds and methods for skin repair |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015537028A JP2015537028A (ja) | 2015-12-24 |
| JP2015537028A5 true JP2015537028A5 (https=) | 2017-01-12 |
Family
ID=49667612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542751A Pending JP2015537028A (ja) | 2012-11-16 | 2013-11-13 | 皮膚修復のための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20140142092A1 (https=) |
| EP (1) | EP2919771A1 (https=) |
| JP (1) | JP2015537028A (https=) |
| CA (1) | CA2891595A1 (https=) |
| WO (1) | WO2014078434A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2890034A1 (en) * | 2012-11-16 | 2014-05-22 | Allergan, Inc. | Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations |
| EP3178463A1 (de) | 2015-12-07 | 2017-06-14 | WDT-Wolz-Dental-Technik GmbH | Verfahren zur herstellung eines keramischen körpers, insbesondere eines dentalkeramikrohlings, mit räumlich gezielt einstellbaren ausprägungsgraden physikalischer eigenschaften |
| CN111050763B (zh) * | 2017-12-26 | 2024-10-11 | 福冈大太朗 | 用于増毛、头皮或皮肤的改质、创伤治愈、骨形成促进或毛发的改质的药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5674888A (en) * | 1995-06-07 | 1997-10-07 | University Of California | Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division |
| NZ541828A (en) * | 2003-03-04 | 2008-06-30 | Pfizer Prod Inc | Use of EP2 selective receptor agonists in medical treatment |
| WO2005116010A1 (en) * | 2004-05-26 | 2005-12-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
| CA2746220A1 (en) * | 2008-12-08 | 2010-07-08 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
| WO2010116270A1 (en) * | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
| KR20130130694A (ko) * | 2010-07-30 | 2013-12-02 | 알러간, 인코포레이티드 | 피부 재생을 위한 화합물과 방법 |
| US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
-
2013
- 2013-11-13 US US14/078,847 patent/US20140142092A1/en not_active Abandoned
- 2013-11-13 CA CA2891595A patent/CA2891595A1/en not_active Abandoned
- 2013-11-13 EP EP13795958.1A patent/EP2919771A1/en not_active Withdrawn
- 2013-11-13 JP JP2015542751A patent/JP2015537028A/ja active Pending
- 2013-11-13 WO PCT/US2013/069919 patent/WO2014078434A1/en not_active Ceased
-
2016
- 2016-06-23 US US15/191,262 patent/US20170143733A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013108394A (ru) | Соединения и способы восстановления кожи | |
| EP3195863A1 (en) | Compounds and methods for skin repair | |
| EA201792559A1 (ru) | Фармацевтические композиции для местного применения | |
| WO2012065065A9 (en) | Methods and compositions for modulating hair growth, wound healing and scar revision | |
| KR20120099454A (ko) | 모발 성장을 촉진하기 위한 조성물 및 방법 | |
| JP2013544842A5 (https=) | ||
| JP2013536183A5 (https=) | ||
| RU2015122627A (ru) | Кожные композиции, содержащие неприродные гигроскопические аминокислоты | |
| PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
| JP2007523832A (ja) | 有効なエンハンサーとしてのサリチル酸誘導体及び方法 | |
| RU2020110783A (ru) | Полутвердая композиция для наружного применения, содержащая антимикробный агент и пирфенидон для лечения хронического повреждения кожи | |
| PH12018500910A1 (en) | Novel method of use and compositions | |
| WO2012125941A1 (en) | Lithium treatment for microbial infections | |
| JP2015537028A5 (https=) | ||
| WO2014168228A1 (ja) | 局所用組成物 | |
| CN106456600B (zh) | 使用青蒿素及其衍生物治疗或预防脂溢性角化病 | |
| JP2015537028A (ja) | 皮膚修復のための組成物および方法 | |
| WO2015181746A1 (en) | Gel form of a heparin sodium salt for dermal administration, and a method for its preparation. | |
| EP3049088B1 (en) | Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring | |
| KR101733189B1 (ko) | 손톱 또는 발톱 성장 촉진용 조성물 | |
| EP4267244A1 (en) | Formulation comprising erbium borate for use in prevention and treatment of wound scars | |
| CN106267172A (zh) | 一种用于预防瘢痕的组合物及其制备方法和应用 | |
| RU2788332C1 (ru) | Мазь для лечения травматического повреждения кожных покровов | |
| RU2005122467A (ru) | Способ химической стабилизации собилизированного ретиноида и водная композиция, полученная этим способом, содержащая по меньшей мере один ретиноид в виде соли | |
| JP6016085B2 (ja) | 抗真菌外用組成物及び抗真菌外用組成物の適用方法 |